Science Daily - Heart Disease

DECEMBER 13, 2023

Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, a form of high blood pressure that occurs in the blood vessels of the lungs and typically affects middle-aged women, according to a new study.

Pulmonary 116

Pulmonary Hypertension Blood Pressure 116

DAIC

JULY 10, 2024

“This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven by underlying disruption in serotonin signaling like pulmonary hypertension,” said Laxminarayan Bhat, Ph.D. Founder, President, and CEO. Brilaroxazine has already received Orphan Drug Designation by the U.S.

Pulmonary 111

Pulmonary Hypertension Pharmacology Biomarkers 111

DAIC

DECEMBER 13, 2023

Pulmonary arterial hypertension, a form of high blood pressure that occurs in the lungs, is a target of research by Cedars-Sinai investigators. Pulmonary arterial hypertension is a rare disease, affecting fewer than 100 people per million. Siegel Family Foundation Distinguished Professor and senior author of the study. “We

Pulmonary 105

Pulmonary Hypertension Blood Pressure Research 105

Med Page Today

DECEMBER 29, 2024

(MedPage Today) -- In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both combination macitentan/tadalafil.

Pulmonary 95

Pulmonary Hypertension 95

Journal of Clinical Investigation - Cardiology

FEBRUARY 1, 2024

Pulmonary arterial hypertension (PAH) is a devastating and progressive disease with limited treatment options. Endothelial haploinsufficiency of RAB7 caused spontaneous pulmonary hypertension (PH) in mice. Here, we explored the role of RAB7 in endothelial cell (EC) function and lung vascular homeostasis.

Pulmonary 98

Pulmonary Hypertension 98

Medical Xpress - Cardiology

JANUARY 19, 2024

A research team has discovered a possible therapeutic target for pulmonary hypertension.

Pulmonary 101

Pulmonary Hypertension Cardiac Function Research 101

Medical Xpress - Cardiology

APRIL 7, 2025

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular changes cause the small pulmonary arteries to narrow.

Pulmonary 72

Pulmonary Hypertension Blood Pressure Circulation 72

Frontiers in Cardiovascular Medicine

FEBRUARY 12, 2025

BackgroundCurrent evidence suggests that cardiovascular disease (CVD) plays a role in the progression of chronic obstructive pulmonary disease (COPD). However, the relationship between CVD and the severity of COPD remains inadequately understood.

Cardiovascular Disease 52

Cardiovascular Disease Pulmonary BMI Hypertension 52

DAIC

MAY 6, 2024

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Medical Xpress - Cardiology

DECEMBER 13, 2023

Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, a form of high blood pressure that occurs in the blood vessels of the lungs and typically affects middle-aged women, according to a study led by Cedars-Sinai investigators.

Pulmonary 85

Pulmonary Hypertension Blood Pressure 85

Medical Xpress - Cardiology

MARCH 29, 2024

Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults.

Pulmonary 77

Pulmonary Hypertension 77

Med Page Today

DECEMBER 12, 2023

(MedPage Today) -- Stable patients with pulmonary vascular disease (PVD) tolerated travel to high altitudes fairly well with frequent monitoring and supplemental oxygen therapy provided as necessary, a field study found. Despite the perceived.

Pulmonary 96

Pulmonary Hypertension 96

HCPLive

JANUARY 31, 2025

Panelists discuss how the coexistence of heart disease and chronic obstructive pulmonary disease (COPD) requires careful management as these conditions significantly impact each other. Key treatable traits in COPD-associated pulmonary hypertension include hypoxemia, inflammation, and right ventricular dysfunction.

Heart Disease 59

Heart Disease Cardiac Function Pulmonary Hypertension 59

Med Page Today

APRIL 1, 2025

(MedPage Today) -- CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients helped delay serious outcomes in the ZENITH trial. Among 172 patients, the drug reduced the.

Pulmonary 59

Pulmonary Hypertension Outcomes 59

Journal of the American Heart Association

FEBRUARY 3, 2025

BackgroundDespite the poor outcomes related to the presence of pulmonary hypertension, it often goes undiagnosed in part because of low suspicion and screening tools not being easily accessible such as echocardiography. Each 15second PCG, recorded using a digital stethoscope, was processed to generate 5second melspectrograms.

Pulmonary 68

Pulmonary Hypertension Echocardiogram Physiology 68

DAIC

FEBRUARY 10, 2025

6, 2025 Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, recently announcedpublication of a peer-reviewed study evaluating its novel algorithm for the detection of pulmonary hypertension (PH). tim.hodson Mon, 02/10/2025 - 12:43 Feb.

Research 64

Research Innovation Pulmonary Hypertension 64

Hypertension Journal

APRIL 23, 2025

Hypertension, Ahead of Print. BACKGROUND:Pulmonary hypertension of the newborn is a life-threatening disorder characterized by elevated pulmonary vascular resistance due to maladaptation of the pulmonary circulation after birth. The effect was mainly mediated by hypoxia after birth in the newborn.

Pulmonary 45

Pulmonary Hypertension Circulation 45

All About Cardiovascular System and Disorders

FEBRUARY 7, 2025

Couple of chest X-rays showing serial changes in pulmonary hypertension over the years and another with features of severe pulmonary hypertension. The post Chest X-ray Features of Pulmonary Hypertension appeared first on All About Cardiovascular System and Disorders.

Pulmonary 52

Pulmonary Hypertension General Cardiology 52

Heart BMJ

AUGUST 26, 2024

LEARNING OBJECTIVES Review the diagnostic pathway for pulmonary arterial hypertension (PAH) in congenital heart disease (CHD). Understand and interpret right heart catheterisation data in pulmonary hypertension related to CHD. Recognise the typical presentation of PAH in patients with CHD.

Congenital Heart Disease 52

Congenital Heart Disease Congenital Pulmonary Hypertension 52

Journal of Cardiothoracic Surgery

APRIL 10, 2025

This study aims to assess the prognostic significance of non-invasive right ventricle-pulmonary artery coupling in patients with pulmonary hypertension associated with left heart disease (PH-LHD) and identify.

Pulmonary 52

Pulmonary Heart Disease Hypertension Research 52

Medical Xpress - Cardiology

MARCH 4, 2025

In the 1980s, when Stella Kourembanas, MD, began her career in neonatology, she cared for newborns with pulmonary hypertension, a disease that results in abnormally high blood pressure in the lung arteries and can lead to heart failure. But pulmonary hypertension still persists.

Pulmonary 56

Pulmonary Hypertension Blood Pressure Heart Failure 56

American College of Cardiology

JUNE 10, 2024

What is the comparative effectiveness of therapies targeting the different treatment pathways in pulmonary arterial hypertension (PAH)?

Pulmonary 49

Pulmonary Hypertension Article 49

HCPLive

MARCH 22, 2024

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

Pulmonary 64

Pulmonary Hypertension 64

Frontiers in Cardiovascular Medicine

MARCH 30, 2025

The independent risk factors for mortality included left ventricular ejection fraction (LVEF), pulmonary hypertension, and low-density lipoprotein (LDL) levels (P<0.05). LVEF, pulmonary hypertension, and LDL levels are critical prognostic factors, offering insights for risk assessment and management in affected children.

Risk Factors 52

Risk Factors Pediatrics Cardiomyopathy Pulmonary 52

American College of Cardiology

AUGUST 7, 2024

In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.

Obesity 58

Obesity Pulmonary Hypertension TAVR 58

American College of Cardiology

JUNE 28, 2024

For the treatment of pulmonary arterial hypertension (PAH), is sildenafil 80 mg TID noninferior to sildenafil 5 mg TID for all-cause mortality?

Pulmonary 54

Pulmonary Hypertension Article 54

American College of Cardiology

MARCH 11, 2025

Pulmonary hypertension (PH) is a rare condition that reportedly affects 1% of the global population, although estimates vary on the basis of age group and setting.

Pulmonary 52

Pulmonary Hypertension Cancer Article 52

Journal of Cardiothoracic Surgery

AUGUST 20, 2024

This research evaluates the effect of balloon pulmonary angioplasty (BPA) on cardiac electrophysiological changes in patients with chronic thromboembolic pulmonary hypertension (CTEPH).

Angioplasty 52

Angioplasty Pulmonary Hypertension Electrophysiology 52

All About Cardiovascular System and Disorders

APRIL 7, 2024

Transcript of the video: Now we will discuss a chest X-ray showing antler sign in pulmonary venous hypertension. So, the shape of the upper lobe vessels in venous hypertension, pulmonary venous hypertension, will be resembling the antlers of the stag. You can see the antlers here.

Pulmonary 52

Pulmonary Hypertension General Cardiology 52

The British Journal of Cardiology

JANUARY 16, 2024

Pulmonary hypertension is a rare disease, associated with a significant deterioration in quality of life, usually not curable and with an ominous prognosis. We present the case of a patient diagnosed with precapillary component pulmonary hypertension, with the finding of an arteriovenous fistula at the peripheral level.

Pulmonary 52

Pulmonary Hypertension Quality of Life Article 52

All About Cardiovascular System and Disorders

FEBRUARY 2, 2024

Biatrial enlargement with pulmonary venous hypertension

Pulmonary 52

Pulmonary Hypertension General Cardiology 52

Open Heart

MAY 7, 2024

Background The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. Treatment escalation was defined as an additional pulmonary arterial hypertension (PAH) drug, pulmonary endarterectomy, percutaneous balloon angioplasty or bilateral lung transplantation.

Heart Monitor 52

Heart Monitor Pulmonary Hypertension Angioplasty 52

Heart BMJ

AUGUST 26, 2024

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complex pulmonary vascular disorder that involves major vessel and microvascular disease components. Fibrotic obstructions resulting from unresolved pulmonary emboli constitute the major vessel disease component.

Pulmonary 52

Pulmonary Hypertension Biomarkers Angioplasty 52

Medical Xpress - Cardiology

JANUARY 22, 2025

A new molecular imaging technique18F-FAPI PETcan detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression.

Pulmonary 52

Pulmonary Hypertension 52

Science Daily - Heart Disease

JANUARY 22, 2025

A new molecular imaging technique -- 18F-FAPI PET -- can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression.

Pulmonary 52

Pulmonary Hypertension 52

American College of Cardiology

JUNE 12, 2024

In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension.

Pulmonary 54

Pulmonary Hypertension Outcomes Article 54

Frontiers in Cardiovascular Medicine

JANUARY 2, 2024

If pulmonary hypertension is additionally involved with vasoplegic syndrome, circulation management becomes much more complicated. The aim of this study is to investigate whether pituitrin is beneficial for the postoperative outcomes in patients with pulmonary hypertension undergoing cardiac surgery.

Pulmonary 59

Pulmonary Hypertension Outcomes Circulation 59